Andrea Stoccoro

Dr. Andrea Stoccoro

Medical Genetics Laboratories, Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, 56126 Pisa, Italy
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
ASAndrea Stoccoro
Andrea Stoccoro
Fabio CoppedèFabio Coppedè
Fabio Coppedè
Epigenetic modifications of the nuclear genome, including DNA methylation, histone modifications and non-coding RNA post-transcriptional regulation, are increasingly being involved in the pathogenesis of several human diseases. Recent evidence suggests that also epigenetic modifications of the mitochondrial genome could contribute to the etiology of human diseases. In particular, altered methylation and hydroxymethylation levels of mitochondrial DNA (mtDNA) have been found in animal models and in human tissues from patients affected by cancer, obesity, diabetes and cardiovascular and neurodegenerative diseases. Moreover, environmental factors, as well as nuclear DNA genetic variants, have been found to impair mtDNA methylation patterns. Some authors failed to find DNA methylation marks in the mitochondrial genome, suggesting that it is unlikely that this epigenetic modification plays any role in the control of the mitochondrial function. On the other hand, several other studies successfully identified the presence of mtDNA methylation, particularly in the mitochondrial displacement loop (D-loop) region, relating it to changes in both mtDNA gene transcription and mitochondrial replication. Overall, investigations performed until now suggest that methylation and hydroxymethylation marks are present in the mtDNA genome, albeit at lower levels compared to those detectable in nuclear DNA, potentially contributing to the mitochondria impairment underlying several human diseases.

2 April 2014 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
Elisa BustaffaElisa Bustaffa
Elisa Bustaffa
ASAndrea Stoccoro
Andrea Stoccoro
Fabrizio BianchiFabrizio Bianchi
Fabrizio Bianchi
LMLucia Migliore
Lucia Migliore

1 November 2013 in Toxicology
Verified
Journal Article
Closed access
ASAndrea Stoccoro
Andrea Stoccoro
HKHanna L. Karlsson
Hanna L. Karlsson
Fabio CoppedèFabio Coppedè
Fabio Coppedè
LMLucia Migliore
Lucia Migliore

8 June 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
LMLucia Migliore
Lucia Migliore
VNVanessa Nicolì
Vanessa Nicolì
ASAndrea Stoccoro
Andrea Stoccoro
Many complex traits or diseases, such as infectious and autoimmune diseases, cancer, xenobiotics exposure, neurodevelopmental and neurodegenerative diseases, as well as the outcome of vaccination, show a differential susceptibility between males and females. In general, the female immune system responds more efficiently to pathogens. However, this can lead to over-reactive immune responses, which may explain the higher presence of autoimmune diseases in women, but also potentially the more adverse effects of vaccination in females compared with in males. Many clinical and epidemiological studies reported, for the SARS-CoV-2 infection, a gender-biased differential response; however, the majority of reports dealt with a comparable morbidity, with males, however, showing higher COVID-19 adverse outcomes. Although gender differences in immune responses have been studied predominantly within the context of sex hormone effects, some other mechanisms have been invoked: cellular mosaicism, skewed X chromosome inactivation, genes escaping X chromosome inactivation, and miRNAs encoded on the X chromosome. The hormonal hypothesis as well as other mechanisms will be examined and discussed in the light of the most recent epigenetic findings in the field, as the concept that epigenetics is the unifying mechanism in explaining gender-specific differences is increasingly emerging.

17 July 2017 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
ASAndrea Stoccoro
Andrea Stoccoro
GSGabriele Siciliano
Gabriele Siciliano
LMLucia Migliore
Lucia Migliore
Fabio CoppedèFabio Coppedè
Fabio Coppedè
Mitochondrial impairment is a feature of neurodegeneration and many investigators have suggested that epigenetic modifications of the mitochondrial DNA (mtDNA) might be involved in late-onset Alzheimer’s disease (LOAD), but evidence in humans is limi

11 January 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FMFrancesca Migheli
Francesca Migheli
ASAndrea Stoccoro
Andrea Stoccoro
Fabio CoppedèFabio Coppedè
Fabio Coppedè
WOWan Adnan Wan Omar
Wan Adnan Wan Omar
AFAlessandra Failli
Alessandra Failli
LMLucia Migliore
Lucia Migliore
There is increasing interest in the development of cost-effective techniques for the quantification of DNA methylation biomarkers. We analyzed 90 samples of surgically resected colorectal cancer tissues for APC and CDKN2A promoter methylation using methylation sensitive-high resolution melting (MS-HRM) and pyrosequencing. MS-HRM is a less expensive technique compared with pyrosequencing but is usually more limited because it gives a range of methylation estimates rather than a single value. Here, we developed a method for deriving single estimates, rather than a range, of methylation using MS-HRM and compared the values obtained in this way with those obtained using the gold standard quantitative method of pyrosequencing. We derived an interpolation curve using standards of known methylated/unmethylated ratio (0%, 12.5%, 25%, 50%, 75%, and 100% of methylation) to obtain the best estimate of the extent of methylation for each of our samples. We observed similar profiles of methylation and a high correlation coefficient between the two techniques. Overall, our new approach allows MS-HRM to be used as a quantitative assay which provides results which are comparable with those obtained by pyrosequencing.